Inclusion Criteria:  Age between 18 and 60 years; Male or female; SARS-CoV-2 infection indicated by rapid test and confirmed by RT-PCR.  Mild or moderate COVID-19:  The oxygen saturation in room air >93%; <30 breaths per minute; No signs of hemodynamic decompensation. Absence of pregnancy in women of childbearing age. Able to understand and comply with the requirements of the protocol. Consent to participate  Exclusion Criteria:  Participants in need of O2 supplementation by catheter or mask, invasive mechanical ventilation, or vasopressors. Onset of symptoms or rapid test or positive RT-PCR for more than 72 hours of inclusion. Participants in use or expected to use within 24 hours prior to the inclusion of drugs that are under clinical investigation as a therapeutic option for the treatment of COVID-19 (eg hydroxychloroquine, chloroquine, ivermectin, nitazoxanide, among others) during the study period; Body mass index less than 19.9 or greater than 35; Comorbidities such as: other serious infections, active malignancies, autoimmune diseases, liver, kidney or heart failure; another systemic disease and / or laboratory abnormality, which, in the investigator's opinion, prevent the patient from participating in the study; Concomitant HIV, HBV or HCV infection. Pregnancy or lactation; Participation in another clinical trial in the 12 months preceding inclusion; Anti-COVID-19 vaccination at any time; Vaccination for any other infection in the 4 weeks prior to inclusion; Any condition that increases the risk of participating in the study, in the opinion of the investigator.